ライフサイエンスコーパス: cryptogenic stroke

1 diagnostic evaluation in 20 to 40% of cases (cryptogenic stroke).

2 e of cardiovascular risk factors in cases of cryptogenic stroke.

3 s essential to determine the pathogenesis in cryptogenic stroke.

4 cardiography in the diagnostic evaluation of cryptogenic stroke.

5 n patients with pacemakers and patients with cryptogenic stroke.

6 troke prevention strategies in patients with cryptogenic stroke.

7 tory comparative studies, and case series on cryptogenic stroke.

8 sure versus medical therapy in patients with cryptogenic stroke.

9 (AF) can be a cause of previously diagnosed cryptogenic stroke.

10 hophysiology have prompted a reassessment of cryptogenic stroke.

11 w-up for detecting atrial fibrillation after cryptogenic stroke.

12 tecting atrial fibrillation in patients with cryptogenic stroke.

13 may represent an opportunity for those with cryptogenic stroke.

14 ggests a causal relationship between PFO and cryptogenic stroke.

15 n attempt to quantitate PFO in patients with cryptogenic stroke.

16 ed risk of recurrent events in patients with cryptogenic stroke.

17 botic strategies in patients with cancer and cryptogenic stroke.

18 stroke in patients 60 years or younger with cryptogenic stroke.

19 elected patients younger than 60 years after cryptogenic stroke.

20 "possible," or "unlikely" cause of otherwise cryptogenic stroke.

21 vale may prevent a substantial proportion of cryptogenic strokes.

22 kes with unclear aetiology are classified as cryptogenic strokes.

23 2 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36 per 1000 population per year, 95

24 = 0.025, log-rank test) and in patients with cryptogenic stroke (10.92 vs 1.82 per 100 patient-years;

25 When applied to patients with cryptogenic stroke, 17% are predicted to be large-vessel

26 I, 10.6%-34.7%) and lowest for patients with cryptogenic stroke (5.8%; 95% CI, 3.0%-8.5%).

27 AF management, <8 days and suspected AF and cryptogenic stroke, 8-21 days).

28 Cryptogenic stroke accounts for 30% to 40% of ischemic s

29 Stroke of undetermined aetiology or 'cryptogenic' stroke accounts for 30-40% of ischaemic str

30 hich there were a total of 506 patients with cryptogenic stroke and 1600 patients in the control grou

31 Of these, 265 patients experienced cryptogenic stroke and 365 experienced known stroke subt

32 To curb this trend, new ways of defining cryptogenic stroke and associated risk factors are neede

33 sis of data from 1015 patients with a recent cryptogenic stroke and biomarker evidence of atrial card

34 We investigated whether patients with cryptogenic stroke and echocardiographic features repres

35 In patients with cryptogenic stroke and evidence of atrial cardiopathy wi

36 zed clinical trial of 1015 participants with cryptogenic stroke and evidence of atrial cardiopathy, d

37 mpared the presence of LSSP in subjects with cryptogenic stroke and non-stroke controls was performed

38 mong 196 patients enrolled, 104 patients had cryptogenic stroke and nonstenosing CAP.

39 ed, randomized study enrolling patients with cryptogenic stroke and patent foramen ovale-related isch

40 at can help identify potential mechanisms in cryptogenic stroke and patients who may be targeted for

41 potentiator of stroke risk in patients with cryptogenic stroke and PFO is a concomitant atrial septa

42 the gold standard for treating patients with cryptogenic stroke and PFO.

43 early 30,000 young patients each year have a cryptogenic stroke and PFO.

44 Cryptogenic Stroke and Underlying Atrial Fibrillation (C

45 and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, a multicenter, rando

46 The terms ESUS and cryptogenic stroke are not synonyms, as the latter also

47 There is persuasive evidence that most cryptogenic strokes are thromboembolic.

48 is increasingly accepted that many of these cryptogenic strokes arise from a distant embolism rather

49 Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated

50 Applying these models to cryptogenic stroke cases yielded that 51.5% fit the vasc

51 Among patients with PFO and cryptogenic stroke, closure reduced recurrent stroke and

52 or dependency at 6 months was similar after cryptogenic stroke compared with non-cardioembolic strok

53 Cryptogenic strokes constitute approximately 40% of isch

54 atent foramen ovale (PFO) is associated with cryptogenic stroke (CS), although the pathogenicity of a

55 onstenosing carotid artery plaques (CAPs) in cryptogenic stroke (CS).

56 However, the definition of cryptogenic stroke did not meet the operational criteria

57 In our cohort, half of young patients with cryptogenic stroke fit the risk factor phenotype of smal

58 Detection of atrial fibrillation after cryptogenic stroke has therapeutic implications.

59 th an embolic stroke of undetermined source (cryptogenic stroke) have a PFO, compared with 25% of the

60 eatment for patients age 18 to 60 years with cryptogenic stroke having a high probability of being PF

61 sed risk of ischemic stroke, and potentially cryptogenic stroke in particular.

62 alysis showed that there is a higher risk of cryptogenic stroke in patients with LSSP than in patient

63 rs to a subgroup of patients with nonlacunar cryptogenic strokes in whom embolism is the suspected st

64 n and have been linked to up to one-third of cryptogenic strokes in younger patients.

65 Modern management strategies for cryptogenic stroke include long-term cardiac monitoring,

66 re several possible mechanisms implicated in cryptogenic stroke, including occult paroxysmal atrial f

67 of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general po

68 n used for cardiac disorders, but its use in cryptogenic stroke is not well established.

69 e precise role of PFO in the pathogenesis of cryptogenic stroke is not yet established.

70 in the prevention of recurrent stroke after cryptogenic stroke is uncertain.

71 cal therapy versus medical therapy alone for cryptogenic stroke is uncertain.

72 t ischemic stroke in patients who have had a cryptogenic stroke is unknown.

73 In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associat

74 agement (n=1197), suspected AF (n=1611), and cryptogenic stroke (n=2205).

75 Cryptogenic stroke, named embolic stroke of undetermined

76 revention of stroke in patients experiencing cryptogenic stroke or ESUS, despite several clinical tri

77 Under the classifications of cryptogenic stroke or ESUS, there is wide heterogeneity

78 y of various MRI techniques in patients with cryptogenic stroke or ESUS.

79 In patients with cryptogenic stroke or TIA who had a patent foramen ovale

80 Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or ol

81 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) an

82 = 3.58, 95% CI = 1.43-8.92, I(2) = 43%) and cryptogenic stroke (OR = 3.98, 95% CI = 1.62-9.77, I(2)

83 s, LSSP was associated with a higher risk of cryptogenic stroke (OR: 1.67; 95% CI: 1.22-2.29; p < 0.0

84 is suspected (as in patients presenting with cryptogenic stroke) or when an ECG diagnosis of unexplai

85 proposed stroke mechanism that may underlie cryptogenic stroke, particularly in younger patients wit

86 hing incidental PFOs from pathogenic ones in cryptogenic stroke patients and for identifying patients

87 Three-year monitoring by ICM in cryptogenic stroke patients demonstrated a significantly

88 mized study to report the detection of AF in cryptogenic stroke patients using continuous long-term m

89 The pooled prevalence of LSSP among cryptogenic stroke patients was 31.6% (95% CI: 20.6-43.8

90 The risk was highest among cryptogenic stroke patients, both for large plaques (HR,

91 rences in stroke prevention strategies among cryptogenic stroke patients.

92 pulation is around 25%, but it is doubled in cryptogenic stroke patients.

93 Of the cryptogenic strokes predicted to be cardioembolic, 27% w

94 Cryptogenic stroke refers to a stroke of undetermined et

95 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophage

96 pirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-

97 The PFO in Cryptogenic Stroke Study was a 42-center study that eval

98 e more prevalent among patients experiencing cryptogenic stroke than among those with strokes of know

99 F in at-risk populations (such as those with cryptogenic stroke), the refinement of AF and stroke pre

100 Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stro

101 RATIONALE: Cryptogenic strokes, those of unknown cause, have been e

102 ed to lower risk of stroke recurrence in our cryptogenic stroke / TIA cohort.

103 n the diagnostic evaluation of patients with cryptogenic stroke to identify potential aetiologies suc

104 ients, closure of patent foramen ovale after cryptogenic stroke, treatment of insulin resistance, and

105 between the LSSP presence and occurrence of cryptogenic stroke using meta-analytical methodologies.

106 schemic stroke after routine PFO closure for cryptogenic stroke was comparable to that observed in cl

107 The cause of cryptogenic stroke was predicted based on a model develo

108 involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a

109 Patients with prior cryptogenic stroke were randomized to control (n=220) or

110 (mean age, 49.3 years) with PFO-attributable cryptogenic stroke who were undergoing percutaneous PFO